

ASX ANNOUNCEMENT 25 November 2019

Lapsing of Hook Options Appendix 3Y

MedAdvisor Limited (ASX: MDR, "MedAdvisor"), Australia's leading digital medication management company, announces that the 714,285 (5m pre 1:7 share consolidation effected on 18 November 2019) 8c Options issued to non-executive Director Ms Sandra Hook and exercisable on or before 24 November 2019 have now lapsed.

The issue of the Options to Ms Hook was approved by members at the Annual General Meeting held 26 October 2016.

Carlo Campiciano

Company Secretary 25 November 2019

---ENDS---

For more information

Carlo Campiciano
Company Secretary
Tel: +61 3 9095 3036
corporate@medadvisor.com.au

Jennifer Duraisingam Corporate Communications Manager Tel: +61 3 9095 3036 jenniferd@medadvisor.com.au

About MedAdvisor

MedAdvisor is a world class medication management platform that empowers users to more simply manage their medication and improve adherence. MedAdvisor's highly automated and intuitive software system connects users to tools and education materials from their local/preferred pharmacy. In Australia, MedAdvisor has connected over one million users through nearly 60% of Australian pharmacies and a network of thousands of GPs. MedAdvisor has recently partnered with Adheris in the US, Zuellig Pharma in Asia and launched into the UK on track to become one of the largest players in the global digital adherence market. In 2018, was recognised in the AFR Fast 100.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	MEDADVISOR LIMITED
ABN	17 145 327 617

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Sandra Hook
Date of last notice	21 November 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect/Direct	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	a. Sandra Margaret Hook and David Glenn McGonigal as trustee of the DST Trustb. Sandra Margaret Hook	
Date of change	25 November 2019	
No. of securities held prior to change	178,571 Ordinary Shares 714,285 8c Options exercisable on or before 24 November 2019	
Class	Options	
Number acquired	Nil	
Number disposed	714,285 8c Options exercisable on or before 24 November 2019	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil	

⁺ See chapter 19 for defined terms.

No. of securities held after change	178,571 Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Lapsing of 714,285 8c Options not exercised on or before 24 November 2019

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

	T
Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – *Closed period

Were the interests in the securities or contracts detailed	No
above traded during a +closed period where prior written	
clearance was required?	

⁺ See chapter 19 for defined terms.

Appendix 3Y Page 2 01/01/2011

If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.